SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Moleculin Completes Patient Dosing in MIRACLE Trial Part A

Moleculin says a comprehensive data readout remains on track for Q1 2027.

MBRX

Related stories